NEW YORK, Feb. 4 - Molecular Staging of New Haven, Conn., and the Scripps Research Institute have won an award totaling up to $2.5 million from the National Institute of Diabetes and Digestive and Kidney disease (NIDDK) to produce large samples of genomic DNA for genetic disease studies, the company said today.
The purpose of the grant, which will be spread over two and a half years, is to provide academic researchers with DNA samples from well-characterized patient population groups, without having to pay private corporations that own most of these samples, according to Molecular Staging.
About 8,000 samples of genomic DNA will be taken from patient samples from Scripps collection, and will be made available to the scientific community. Ernest Beutler, chairman of the department of molecular and experimental medicine at Scripps, will supervise this process, making sure to only provide samples from patients who have given informed consent.
Molecular Staging will use its.REPLI-g whole genome amplification method in order to copy the samples, the company said.